公开(公告)号：WO2021155581A1

公开(公告)日：2021-08-12

申请号：PCT/CN2020/074516

申请日：2020-02-07

Applicant: COTHERA BIOSCIENCE, INC. ,  LI, Xiang ,  CHEN, Yiyou

Inventor： LI, Xiang ,  CHEN, Yiyou

IPC: C12N15/19 ,  C12Q1/68 ,  A61P35/00

Abstract: Provided are combination therapies and secondary biomarkers for treating MYCC-associated diffuse large B-cell lymphoma (DLBCL) with YM155-based therapies, and related kits, compositions, and methods of use thereof.

公开(公告)号：WO2021068868A1

公开(公告)日：2021-04-15

申请号：PCT/CN2020/119874

申请日：2020-10-08

Applicant: COTHERA BIOSCIENCE, INC. ,  CHEN, Yiyou

Inventor： JIANG, Chun

IPC: A61K39/395 ,  A61P35/00

Abstract: It relates to a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.

公开(公告)号：WO2021068867A1

公开(公告)日：2021-04-15

申请号：PCT/CN2020/119873

申请日：2020-10-08

Applicant: COTHERA BIOSCIENCE, INC. ,  CHEN, Yiyou

Inventor： JIANG, Chun

IPC: C07K16/40 ,  A61K31/506 ,  A61K31/167 ,  A61K39/395 ,  A61P35/00

Abstract: Provided is a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.

公开(公告)号：WO2021155580A1

公开(公告)日：2021-08-12

申请号：PCT/CN2020/074515

申请日：2020-02-07

Applicant: COTHERA BIOSCIENCE, INC. ,  LI, Xiang ,  JIANG, Chun ,  CHEN, Yiyou

Inventor： LI, Xiang ,  JIANG, Chun ,  CHEN, Yiyou

IPC: A61P35/00 ,  A61K31/497 ,  A61K45/06

Abstract: Provided are methods of using an anti-cancer agent's cell cycle-related, cell-killing activity to identify it as an effective combination with YM155 monobromide for treating MYC-associated cancers, and related kits, compositions, methods of screening, and methods for treating cancer in a subject in need thereof.